Recent pre-clinical [298,299] and clinical studies [300] explored the applicability of olaparib synthetic lethality to cancers with disrupted ATM protein expression, specifically gastric cancer and mantle cell lymphoma (MCL). Here, ATM is linked to mantle cell lymphoma.